当前位置:首页 >财报库 > 报告详情

默克集团Merck Group(MRK)2025年年度报告「FWB」(英文版)(558页).pdf

上传人: 1****1 编号:1155314 2026-03-12 558页 9.32MB

下载:

1、Annual Report2025KEY FIGURES 2025Merck GroupNet sales millionMerck GroupMerck GroupEBITDA pre1 million1 Not defined by IFRS Accounting Standards.Change million20252024 million%Net sales21,102 21,156-54-0.3%Operating result(EBIT)13,601 3,645-44-1.2%Margin(%of net sales)117.1%17.2%EBITDA25,899 5,779 1

2、20 2.1%Margin(%of net sales)128.0%27.3%EBITDA pre 16,109 6,072 37 0.6%Margin(%of net sales)128.9%28.7%Profit after tax2,615 2,786-171-6.1%Earnings per share(in)6.00 6.39-0.39-6.1%Earnings per share pre()18.34 8.63-0.29-3.4%Operating cash flow 3,932 4,586-654-14.3%1 Not defined by IFRS Accounting Sta

3、ndards(IFRS Accounting Standards).2 Not defined by IFRS Accounting Standards;EBITDA corresponds to operating result(EBIT)adjusted by depreciation,amortization,impairment losses,and reversals of impairment losses.A strong teamLife ScienceNet sales per regionHealthcareElectronicsemployees62,461Share o

4、fnet sales42%Share ofnet sales41%Share ofnet sales17%Share ofEBITDA pre40%Share ofEBITDA pre47%Share ofEBITDA pre13%countries65Asia-Pacific 6,936 millionEurope 6,417 millionNorth America 5,517 millionLatin America 1,447 millionMiddle East and Africa785 millionAT A GLaNCETogether,we impact life and h

5、ealth with science.We help to create,improve and prolong lives.We are advancing digital living.Table of contents To our Shareholders 6 Letter of the CEO 9 Executive Board 10 Our Shares Combined Management Report 14 Fundamental Information about the Group 14 Company Profile and Structure 25 Strategy

6、32 Internal Management System 39 Research and Development 51 Report on Economic Position 51 Macroeconomic and Sector-Specific Environment 55 Review of Forecast against Actual Business Development 59 Course of Business and Economic Position 59 Merck Group 70 Life Science 74 Healthcare 79 Electronics

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **财务表现**:2025年净销售额211.02亿欧元(同比-0.3%),EBITDA pre 61.09亿欧元(同比+0.6%,毛利率28.9%),净利润26.15亿欧元(同比-6.1%)。 2. **业务板块**: - **生命科学**(占销售额42%):有机增长4.0%,工艺解决方案增长10.7%,收购JSR色谱业务。 - **医疗健康**(占销售额41%):有机增长3.7%,收购SpringWorks Therapeutics(罕见病药物Ogsiveo®和Gomekli®)。 - **电子**(占销售额17%):有机下降0.6%,半导体材料增长8.2%,台湾半导体解决方案基地启用。 3. **战略重点**:聚焦三大增长驱动力(生命科学工艺解决方案、医疗健康罕见病、电子半导体解决方案),中期目标中单位数有机增长,资本支出逐步正常化。 4. **可持续发展**:2020年以来Scope 1&2碳排放减半,可再生能源占比64%,目标2030年达80%。
**Merck增长引擎?** **罕见病新药进展?** **半导体材料突破?**
客服
商务合作
小程序
服务号
折叠